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Isocitrate dehydrogenase (IDH) mutations are found in low-grade gliomas, and the 
product of the IDH mutant (MT), 2-hydroxyglutarate (2-HG), is the first known oncometabolite. 
However, the roles of the IDH wild type (WT) in high-grade glioblastoma, which rarely has 
the IDH mutation, are still unknown. To investigate possible pathways related to IDH WT in 
gliomas, we carried out bioinformatics analysis, and found that IDH1 has several putative 
calmodulin (CaM) binding sites. Pull-down and quantitative dissociation constant (Kd) 
measurements using recombinant proteins showed that IDH1 WT indeed binds to CaM with a 
higher affinity than IDH1 R132H MT. This biochemical interaction was demonstrated also in 
the cellular environment by immunoprecipitation with glioblastoma cell extracts. A synthetic 
peptide for the suggested binding region interfered with the interaction between CaM and IDH1, 
confirming the specificity of the binding. Direct binding between the synthetic peptide and 
CaM was observed in an NMR binding experiment, which additionally revealed that the 
peptide initially binds to the C-lobe of CaM. The physiological meaning of the CaM-IDH1 WT 
binding was shown with trifluoperazine (TFP), a CaM antagonist, which disrupted the binding 
and inhibited survival and migration of glioblastoma cells with IDH1 WT. As CaM signaling 
is activated in glioblastoma, our results suggest that IDH1 WT may be involved in the CaM-





Isocitrate dehydrogenase (IDH) 
catalyzes the oxidative decarboxylation of 
isocitrate, yielding alpha-ketoglutarate and 
CO2. The reaction, which involves NAD(P)H 
as a coenzyme, is reversible under 
physiological conditions. IDH has drawn 
considerable interest, as its mutation, 
particularly R132 H mutation (MT) in IDH1, 
has been found associated with brain cancer 
[1]. Initially, IDH1 was suggested to be a 
tumor suppressor, and its mutant form (IDH1 
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MT) was reported to suppress the activity of 
wild-type IDH1 (IDH1 WT) [2]. However, 
IDH1 MT was soon shown to produce 2-
hydroxyglutarate (2-HG) through its 
neomorphic activity [3], 2-HG becoming 
known as the first oncometabolite. Since then, 
much research has been carried out to 
establish the causal roles of IDH MT and 2-
HG in glioma tumorigenesis [4,5]. However, 
direct tumorigenic roles have not been firmly 
established in glioma [6], though an inhibitor 
of IDH1 MT has been developed as a drug 
for use in acute myeloid leukemia (AML) 
with IDH1 mutation [7]. Interestingly, IDH1 
mutations have been found mainly in low-
grade (grade I and II) or secondary glioma, 
and quite rarely in high-grade primary 
gliomas (grade IV), including glioblastoma 
multiforme (GBM) [8]. Furthermore, the 
wild-type IDH allele seems to be required for 
the high levels of 2-HG found in glioma with 
IDH MT [9]. Therefore, most research on the 
relationship between IDH and glioma has 
focused on IDH MT and low-grade gliomas, 
and relatively little is known on the roles of 
IDH WT in more malignant high-grade 
gliomas. 
Calmodulin (CaM) is a well-known 
Ca2+-binding protein that mediates various 
cell-signaling pathways by interacting with 
its targets. CaM’s level is higher in malignant 
GBM than in normal brain or low-grade 
glioma, and its expression levels are strongly 
correlated with glioma cell’s migration 
capabilities [10]. Higher expression of CaM 
is associated with poorer prognosis and 
shorter survival in glioma patients [10]. 
Several aspects of CaM-signaling have been 
correlated with growth and migration of 
gliomas. [11,12]. CaM-dependent kinase II 
(CaMKII) binds and regulates CLC-3, a 
chloride channel elevated in grade IV glioma, 
and pharmacological inhibition of CaMKII 
reduces glioma cell migration [11]. CaM 
itself binds K-ras [13,14], whose signaling 
has been found to be important in 
glioblastoma maintenance [15]. Disruption 
of CaM-K-ras interaction might have a 
potential role in glioblastoma, as CBP501 
that binds CaM and blocks the interaction is 
in clinical trials for non-small-cell lung 
cancer [16,17]. Actually, trifluoperazin 
(TFP), an anti-schizophrenic drug with well-
known CaM antagonist activity, has 
exhibited anti-glioblastoma effects both in 
vitro and in vivo [18]. Therefore, CaM might 
interact with other proteins, thereby affecting 
the growth, migration and malignancy of 
glioblastoma. In this study, we investigated 
the direct interaction between CaM and 
IDH1 WT, known to be correlated with 
malignant glioma, and its implications for 
glioma growth and migration. 
 
2. Materials and methods 
 
2.1. Protein expression and purification 
 
Purified CaM protein was obtained 
as described before [19]. IDH1 WT and 
R132H MT proteins were prepared as 
described in detail in Supplementary 
Information. All of the protein samples were 
treated with 5 mM EGTA at pH 8.0 to remove 
inherently bound Ca2+. 
  
2.2. Pull-down assay 
 
Immobilized CaM resin was 
prepared using purified CaM and NHS-
activated sepharose 4 fast resin (GE 
Healthcare Life Sciences), as described 
previously [19]. Detailed methods are 




U87 cells expressing IDH1 WT and 
R132H MT [20] were applied to the co-
immunoprecipitation method according to 
the manufacturer’s protocol. Procedures in 
detail are described in Supplementary 
Information. 
 
2.4. Surface Plasmon Resonance (SPR) 
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The protein interaction was analyzed 
by Reichert SR7500DC spectrometry 
(Reichert Technologies, Depew, NY, USA) 
following the manufacturer’s instructions. 
Detailed procedures are described in 
Supplementary Information.   




quantum coherence (HSQC) spectra were 
obtained on an 800 MHz spectrometer 
(Bruker, Billerica, MA, USA) equipped with 
a cryogenic probe. Additional information is 
provided in Supplementary Information. 
   
2.6. Scratch-wound-healing assay 
 
U87 cells over-expressing IDH1 WT 
were treated for scratch-wound-healing assay. 
Detailed methods are described in 
Supplementary Information.  
 
2.7. Cell viability and proliferation assay 
 
Cell viability was assessed using an 
MTT assay, and proliferation was measured 
using crystal violet staining. Both assays are 
well-established, and were performed using 
standard protocols. Detailed procedures are 





3.1. Prediction of binding between CaM and 
IDH1.  
 
To find possible binding targets of 
IDH relevant to its involvement in glioma 
severity, we analyzed its sequence for the 
presence of protein-interaction sites. The 
analysis with Scansite [21] presented 
possible kinase interaction and modification 
sites. Among them, we took notice of CaM-
dependent kinase 2 (Fig. 1A), particularly as 
a recent paper suggested a relationship 
between CaM signaling and IDH1 mutant 
status in glioma [22]. We then further 
analyzed the IDH1 sequence for the presence 
of possible CaM-binding sites, as the 
requirements for CaM-binding are well 
established (Fig. 1B). Interestingly, amino 
acids between G339 and L346 in IDH1 
exhibited a stretch of very high probability of 
CaM binding, with 8 consecutive amino 
acids showing scores of 9. There were no 
other regions with such a high binding score. 
The analysis suggested that there might be 
specific binding between IDH1 and CaM 
involving this region (see again Fig. 1B). 
 
3.2. Biochemical assay for binding between 
CaM and IDH1 WT/MT.  
 
To test the suggested interaction 
between CaM and IDH1 experimentally, we 
prepared recombinant proteins for both CaM 
and IDH1. For IDH1, we made both wild-
type (WT) and mutant (R132H MT) proteins, 
since they are associated with different 
clinical outcomes of glioma [1]. In addition, 
CaM signaling (i.e.CaMKK2 expression) 
was shown to differ between IDH1 WT and 
MT glioma cells [22]. The bindings were 
monitored by pull-down assay employing 
resins with immobilized CaM (Fig. 1C). 
Neither IDH1 WT nor MT bound to 
sepharose resin without immobilized CaM, 
but more WT bound to the CaM-sepharose 
than R132H. The absence of BSA binding to 
CaM-immobilized resin excluded possible 
non-specific binding effects. The binding 
was weaker in the presence of salt (100 or 
150 mM), but IDH1 WT still exhibited 
significant binding, whereas R132H did not 
(Fig. S1). To investigate the binding 
interaction more quantitatively, we also 
obtained the dissociation constant (Kd) using 
surface plasmon resonance (SPR). 
Consistent with the above pull-down and 
immunoprecipitation, IDH1 WT exhibited an 
order-of-magnitude-higher affinity than 
R132H MT toward CaM, the Kd values 







Figure 1. Bioinformatic sequence analysis of IDH1 and identifications of the binding between of IDH1 
proteins with CaM. (A) Motif scan results of IDH1. Signaling domains of IDH1 was analyzed using Scansite 
program, and the predicted kinase interaction and modification motifs are shown. (B) Predicted CaM-binding sites 
of IDH1. The numbers represent the probability of CaM binding. The putative binding site is boxed as dotted 
orange lines. (C) Pull-down assay for the binding between of IDH1 proteins with CaM. Resin-immobilized CaM 
was incubated with recombinant IDH1 WT and R132H MT. Sepharose CL-4B resin without immobilized CaM 
was used as the negative control. BSA was used to test the non-specific binding. Input shows the molecular sizes 
of the proteins. (D) Quantitative binding analysis for the CaM-IDH1 interaction using Surface Plasmon Resonance 
(SPR). Responses upon the injection of the analytes (IDH1 WT/R132H MT) are presented (RU; arbitrary unit). 
Binding affinity were calculated as KD 238 ± 2 nM (WT) and 2330 ± 2 nM (R132H). (E-F). Co-
immunoprecipitation of CaM and IDH1 proteins in WT/R132H-expressing U87 cells. (E) Specificities of 
antibodies against IDH1 WT and R132H MT were tested using the lysates from parental (U87), IDH1 WT, and 
R132H MT U87 cells. (F) The cell lysates were co-immunoprecipitated using CaM antibody and protein A/G 
agarose and blotted with antibodies against IDH1 WT and R132H. 
 
3.3. Binding of CaM and IDH1 in a cellular 
environment.  
 
To test IDH1-CaM binding in an 
actual cellular environment, IDH1 WT and 
MT proteins were heterologously expressed 
in U87 glioma cells and the binding with 
endogenous CaM was tested by 
immunoprecipitation. The glioma cell line 
was chosen because IDH1 mutation status 
greatly affects glioma prognosis, IDH1 MT 
being associated with better prognosis [1]. 
The two proteins were co-
immunoprecipitated with CaM antibody, and 
then a Western blot was carried out using 
antibodies specific to either IDH1 WT or 
R132H MT (Fig. 1E-F). As shown in Figure 
2D, binding was observed between IDH1 
WT and CaM, but not between IDH1 MT and 
CaM. The data confirmed binding between 
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IDH1 and CaM in the native cellular 
environment and its dependency on mutation 
status. 
 
3.4. Confirmation of the binding site. 
 
Having confirmed the binding 
between CaM and IDH1 WT, we investigated 
whether the binding region predicted above 
is actually involved in the interaction. To that 
end, we synthesized a peptide corresponding 
to the site and flanking region with the 
sequence WTRGLAHRAKLDNNKE. In the 
three-dimensional structure of IDH1 (PDB 
ID: 1T0L), the peptide was located in a 
region including two helices with a loop 
between them. The site also turned out to be 
surface-exposed and, thus, available for 
binding interaction (Fig. 2A). The actual 
binding of this peptide to CaM was tested 
with a pull-down competition assay. The 
addition of the peptide to the CaM-IDH1 
mixture significantly decreased the binding 
between the two proteins (Fig. 2B). To 
confirm that the binding between the peptide 
and CaM is direct, NMR spectroscopy was 
employed with 15N-labeled CaM. The 
addition of the excess peptide (2 mM) to 
CaM (200 μM) induced readily visible 
changes in the CaM spectrum (Fig. 2C). At 
an equimolar concentration (200 μM), the 
spectral changes were smaller. Importantly, 
this NMR experiment also provided the 
information on the CaM residues involved in 
the peptide-binding, as the interaction leads 
to peak changes (Fig. 2D). When mapped 
onto the three-dimensional structure of CaM, 
those residues were found in a small patch on 
the C-lobe (Fig. 2E) of CaM, which suggests 
that CaM-IDH1 binding occurs, at least 
initially, through the C-lobe. The results also 
suggest that CaM-IDH1 binding is calcium-
independent, as the spectra were acquired in 
the presence of EGTA. Overall, the 
biochemical and spectroscopic binding 
experiments showed that CaM-IDH1 binding 
is direct, is mediated by the suggested 
peptide region, and is calcium-independent. 
 
3.5. CaM antagonist TFP inhibits CaM-
IDH1 WT interaction and reduces migration 
of IDH1-WT-over-expressed U87 cells.  
 
After confirming the interaction of 
CaM with IDH1 WT, and the much weaker 
interaction with IDH1 MT, we investigated 
the functional aspects of the interaction. We 
first tested the effects of a functional CaM 
antagonist, TFP, on the binding between the 
two proteins. To determine if this antagonist 
can inhibit CaM-IDH1 binding, we 
performed a pull-down assay in the presence 
of TFP. The results showed that CaM-IDH1 
WT binding is indeed inhibited by TFP (Fig. 
3A). As TFP induces major conformational 
changes in CaM and thereby inhibits CaM-
target binding [23], our result suggests that 
TFP can affect the functions of CaM-IDH1 
WT complex. It has been shown that glioma 
with IDH1 WT is much more aggressive than 
with IDH1 MT, and that TFP exhibits anti-
metastatic activity [24] . In addition, CaM, 
through its interaction with p68 helicase, is 
involved in cancer metastasis and migration, 
and this interaction can be abrogated by a 
peptide [25]. Therefore, we tested if TFP’s 
inhibition of the interaction between CaM 
and IDH1 has any implications for the 
migration of U87 glioblastoma cells. We 
performed a scratch-wound-healing assay on 
U87 cells transfected with IDH1 WT in the 
presence of TFP. As shown on Fig. 3, TFP 
inhibited the migration of U87 cells 
expressing IDH1 WT (Fig. 3B-C). The TFP’s 
effect on cell proliferation was also tested 
using crystal violet staining, and the result 
shows that TFP inhibited the IDH1 WT cell 
proliferation in a concentration dependent 
manner (Fig. 3D). We also confirmed the 
effect of TFP on native U87 cells not 





Figure 2. Binding sites for the interaction between IDH and CaM. (A) The predicted CaM-binding site on the 
IDH1 three-dimensional structure is shown in red (PDB ID: 1T0L). (B) The pull-down competition experiment 
with immobilized-CaM for the binding to IDH1 WT (0.5 mM) in the absence and presence of the IDH1 peptide 
(5 mM). (C-D) 1H-15N HSQC NMR spectrum of 15N-labeled CaM (200 μM) in the absence (black) and presence 
of the IDH-peptide (red) (C: 2 mM; D: 200μM of IDH-peptide). (D) The CaM residues that changed upon the 
IDH1 peptide binding are indicated. (E) The changed residues in (D) are indicated in magenta on the CaM PDB 







Figure 3. Effects of TFP in protein-protein interaction, cell migration and proliferation. (A) Pull-down assay 
for the CaM-IDH1 binding with immobilized-CaM in the presence or absence of TFP. The lower bar graph is the 
densitometric representation of the three independent pull-down experiments (*; p < 0.05). (B-C) Migration of 
IDH1-WT-expressing U87 cells were assessed by scratch-wound-healing assay. The cells were photographed (B) 
and analyzed using Image J (C). (D) Proliferation of IDH1-WT-expressing U87 cell measured by crystal violet 





IDH1 MT has drawn considerable 
attention due to its neomorphic activity in 
generating 2-HG and its involvement in the 
tumorigenesis of glioma and other cancers. 
However, it has also been recognized that 
mutation is almost exclusively found in low-
grade glioma and that patients with IDH1 
mutation have better prognoses than those 
with IDH1 WT. Interestingly, the gene level 
of IDH1 itself is significantly higher in GBM, 
the most aggressive form of glioma, than in 
lower-grade gliomas or normal-patient 
samples (Fig. S3). Therefore, it seemed 
worthwhile to investigate the difference 
between IDH1 WT and MT in the context of 
protein interactions implicated in gliomas. 
Our results showed that IDH1 WT and MT 
have different binding activities toward CaM 
whose expression is associated with poorer 
prognosis and shorter survival of glioma 
patients [10].  
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Then, how could just one residue mutation 
can lead to such a significant binding affinity 
difference and biological function? Despite 
the small-scale one-residue mutation, the 
structural changes are propagated to distant 
regions with significant differences in the 
alignment of the secondary structural 
elements (Fig. 4). As is consistent with its 
involvement in binding, the CaM-binding 
site in IDH1 is located in a cavity region of 
IDH1. In addition, the three-dimensional 
conformation of the amino acid residues in 
the region seems to affect the accessibility of 
the cavity. For example, K345 in the binding 
site is solvent-exposed in IDH1 WT, whereas 
it is buried and inaccessible for binding in 
IDH1 MT. Also, IDH1 MT has a protruding 
amino acid, K350, in the cavity region, which 
contributes to the smaller cavity and possible 
inhibition of protein interaction. These 
differences seem to generate the larger and 
more accessible cavity in the CaM-binding 
region in IDH1 WT. Therefore, IDH1 WT 
can have a higher binding affinity, even 
though the sequences in the CaM-binding 
region are the same between the IDH1 WT 





Figure 4. Comparison of the three dimensional structures of IDH1 WT (PDB ID: 1T0L) and R132H MT 
(PDB ID: 3MAP). IDH1 proteins are displayed with cartoon and surface. The peptide region for the CaM-binding 
is shown in red (amino acids; W336 ~ E352), magenta (K350), and cyan (K345). The structural difference of the 
cavity around the peptide region is indicated by yellow circles on IDH1 WT (A) and R132H MT (B). The amino 
acid residue 132 that is mutated in R132H is shown by green stick. 
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To further confirm the binding 
between CaM and IDH1 and to understand 
its meaning biologically, we investigated the 
effects of TFP, an established CaM 
antagonist. Conventionally, TFP has been 
used as an anti-psychotic drug, and some 
anti-psychotic drugs, such as TFP, 
thioridazine, and phenoxybenzamine, have 
been shown to inhibit growth of highly 
malignant glioblastoma cells in vivo and/or in 
vitro [18,26,27]. We obtained consistent 
results for the inhibitory effect of TFP on 
U87 glioblastoma cell survival and migration. 
We also showed that, in addition to these 
phenotypic effects, TFP actually interferes 
with the molecular interaction between CaM 
and IDH1 WT, providing a mechanistic 
insight in the TFP’s anti-glioma activity. 
Proteins bound and regulated by CaM such 
as K-ras and CLC-3, have been known to be 
associated with glioblastoma migration and 
malignancy [13-17]. Furthermore, a CaM-
dependent kinase II, CaMKK2, which 
functions as a signaling hub in diverse 
cellular regulatory pathways, is expressed 
differentially in IDH1 WT and MT glioma 
cells [22], suggesting that CaM signaling and 
binding proteins influence glioma 
malignancy and aggressiveness. The 
expression level of CaM seems also to be 
elevated in high-grade gliomas [10], though 
some studies have reported the opposite trend 
[18]. Still, it should be noted that inhibitions 
of CaM by an inhibitor or shRNA leads to 
reduction of migration and increased survival 
in vivo [10]. Considering all of these facts, 
we are tempted to speculate that IDH1 WT, 
but not IDH1 MT, may be a previously 
unknown target of CaM in high- grade 
gliomas, and that pharmacological disruption 
of CaM-IDH1 WT interaction may reduce 
the migration and aggressiveness of glioma 
cells. As the tumor-association of IDH1 MT 
has been found mostly in low-grade gliomas 
with better prognoses, there has even been a 
suggestion that IDH1 mutation might 
actually be a protective mechanism for 
overall patient survival [28]. More research 
into the roles of IDH WT in glioma 
tumorigenesis is warranted to determine if 
IDH mutation can act as a regulator of glioma 
aggressiveness by controlling the interaction 
between IDH and its binding proteins such as 
CaM. 
We also obtained more detailed 
insight into how CaM interacts with IDH1 
WT and how it can be disrupted by CaM-
antagonist TFP. At a low stoichiometry (1:1), 
the IDH1 peptide induced chemical shifts 
only on residues at the C-lobe of CaM, 
especially those from M145 (1st M) to A148 
(see Fig. 2D and E). These residues coincide 
with the major binding residues for TFP at 
low stoichiometry, in the absence of calcium 
(M145 and M146 correspond to M144 and 
M145, respectively, in the original reference, 
due to a one-residue numbering difference) 
[29,30]. Therefore, TFP seems to directly 
compete with the IDH1 peptide at the same 
binding site on the C-lobe. At a higher 
stoichiometry (1:10), the IDH1 peptide 
induced much larger changes over residues in 
both the C- and N-lobes. Interestingly, up to 
four molecules of TFP can bind to CaM in the 
presence of calcium, and this higher 
stoichiometry interaction involves residues 
on both the C- and N-lobes [29]. The 
calcium-independent initial binding to the C-
lobe and the subsequent binding to the N-
lobe also has been shown for other CaM 
interactions [31,32]. The IDH1 peptide 
exhibited a similar stepwise binding mode, 
except that it did not require calcium for the 
N-lobe interaction. Instead, a higher 
concentration drove the interaction toward 
the two-lobe binding mode, which might 
represent another mechanism of CaM-
partner interaction.  
In conclusion, the identified new 
interaction between CaM and IDH1 WT, but 
not IDH1 MT, can be associated with the 
difference between high- and low-grade 
gliomas. Therefore, CaM’s pharmacological 
inhibition could suggest a new strategy for 
the control of gliomas’ aggressive properties. 
10 
 






This research was supported by grants from 
the National Research Foundation of Korea 
(NRF) (2017R1C1B1008004 and NRF-
2018R1A3B1052328). The authors are 
grateful also to Dr. Chul-Kee Park at Seoul 
National University Hospital for providing 
the U87 IDH1 WT/R132H-expressing cell 
lines. 
 
This article contains Supporting Information 





[1] D.W. Parsons, S. Jones, X. Zhang, et al., An 
integrated genomic analysis of human 
glioblastoma multiforme, Science 321 (2008) 
1807-1812. 
[2] S. Zhao, Y. Lin, W. Xu, et al., Glioma-derived 
mutations in IDH1 dominantly inhibit IDH1 
catalytic activity and induce HIF-1alpha, Science 
324 (2009) 261-265. 
[3] L. Dang, D.W. White, S. Gross, et al., Cancer-
associated IDH1 mutations produce 2-
hydroxyglutarate, Nature 462 (2009) 739-744. 
[4] P. Koivunen, S. Lee, C.G. Duncan, et al., 
Transformation by the (R)-enantiomer of 2-
hydroxyglutarate linked to EGLN activation, 
Nature 483 (2012) 484-488. 
[5] J.A. Losman, R.E. Looper, P. Koivunen, et al., 
(R)-2-hydroxyglutarate is sufficient to promote 
leukemogenesis and its effects are reversible, 
Science 339 (2013) 1621-1625. 
[6] M. Sasaki, C.B. Knobbe, M. Itsumi, et al., D-
2-hydroxyglutarate produced by mutant IDH1 
perturbs collagen maturation and basement 
membrane function, Genes Dev 26 (2012) 2038-
2049. 
[7] C.D. DiNardo, E.M. Stein, S. de Botton, et al., 
Durable Remissions with Ivosidenib in IDH1-
Mutated Relapsed or Refractory AML, N Engl J 
Med 378 (2018) 2386-2398. 
[8] H. Yan, D.W. Parsons, G. Jin, et al., IDH1 and 
IDH2 mutations in gliomas, N Engl J Med 360 
(2009) 765-773. 
[9] G. Jin, Z.J. Reitman, C.G. Duncan, et al., 
Disruption of wild-type IDH1 suppresses D-2-
hydroxyglutarate production in IDH1-mutated 
gliomas, Cancer Res 73 (2013) 496-501. 
[10] T. Li, L. Yi, L. Hai, et al., The interactome and 
spatial redistribution feature of Ca2+ receptor 
protein calmodulin reveals a novel role in 
invadopodia-mediated invasion, Cell Death Dis 
9 (2018) 292. 
[11] V.A. CuddapahandH. Sontheimer, Molecular 
interaction and functional regulation of ClC-3 
by Ca2+/calmodulin-dependent protein kinase II 
(CaMKII) in human malignant glioma, J Biol 
Chem 285 (2010) 11188-11196. 
[12] X. Sun, D. Zhao, Y.L. Li, et al., Regulation of 
ASIC1 by Ca2+/calmodulin-dependent protein 
kinase II in human glioblastoma multiforme, 
Oncol Rep 30 (2013) 2852-2858. 
[13] P. Villalonga, C. Lopez-Alcala, M. Bosch, et 
al., Calmodulin binds to K-Ras, but not to H- or 
N-Ras, and modulates its downstream signaling, 
Mol Cell Biol 21 (2001) 7345-7354. 
[14] M.T. Wang, M. Holderfield, J. Galeas, et al., 
K-Ras Promotes Tumorigenicity through 
Suppression of Non-canonical Wnt Signaling, 
Cell 163 (2015) 1237-1251. 
11 
 
[15] S.L. HolmenandB.O. Williams, Essential role 
for Ras signaling in glioblastoma maintenance, 
Cancer Res 65 (2005) 8250-8255. 
[16] N. Mine, S. Yamamoto, N. Saito, et al., 
CBP501-calmodulin binding contributes to 
sensitizing tumor cells to cisplatin and 
bleomycin, Mol Cancer Ther 10 (2011) 1929-
1938. 
[17] N. Saito, N. Mine, D.W. Kufe, et al., CBP501 
inhibits EGF-dependent cell migration, invasion 
and epithelial-to-mesenchymal transition of 
non-small cell lung cancer cells by blocking 
KRas to calmodulin binding, Oncotarget 8 (2017) 
74006-74018. 
[18] S. Kang, J. Hong, J.M. Lee, et al., 
Trifluoperazine, a Well-Known Antipsychotic, 
Inhibits Glioblastoma Invasion by Binding to 
Calmodulin and Disinhibiting Calcium Release 
Channel IP3R, Mol Cancer Ther 16 (2017) 217-
227. 
[19] S. Kang, J. Kang, S.H. Yoo, et al., 
Recombinant preparation and characterization 
of interactions for a calmodulin-binding 
chromogranin A peptide and calmodulin, J Pept 
Sci 13 (2007) 237-244. 
[20] H. Wen, H.R. Cho, T. Yun, et al., 
Metabolomic comparison between cells over-
expressing isocitrate dehydrogenase 1 and 2 
mutants and the effects of an inhibitor on the 
metabolism, J Neurochem 132 (2015) 183-193. 
[21] J.C. Obenauer, L.C. CantleyandM.B. Yaffe, 
Scansite 2.0: Proteome-wide prediction of cell 
signaling interactions using short sequence 
motifs, Nucleic Acids Res 31 (2003) 3635-3641. 
[22] J. Ren, M. Lou, J. Shi, et al., Identifying the 
genes regulated by IDH1 via gene-chip in 
glioma cell U87, Int J Clin Exp Med 8 (2015) 
18090-18098. 
[23] M. Vandonselaar, R.A. Hickie, J.W. Quail, et 
al., Trifluoperazine-induced conformational 
change in Ca2+-calmodulin, Nature Struct Biol 1 
(1994) 795-801. 
[24] A. Pulkoski-Gross, J. Li, C. Zheng, et al., 
Repurposing the antipsychotic trifluoperazine 
as an antimetastasis agent, Mol Pharmacol 87 
(2015) 501-512. 
[25] H. Wang, X. Gao, J.J. Yang, et al., Interaction 
between p68 RNA helicase and Ca2+-
calmodulin promotes cell migration and 
metastasis, Nat Commun 4 (2013) 1354. 
[26] H.W. Cheng, Y.H. Liang, Y.L. Kuo, et al., 
Identification of thioridazine, an antipsychotic 
drug, as an antiglioblastoma and anticancer 
stem cell agent using public gene expression 
data, Cell Death Dis 6 (2015) e1753. 
[27] X.B. Lin, L. Jiang, M.H. Ding, et al., Anti-
tumor activity of phenoxybenzamine 
hydrochloride on malignant glioma cells, 
Tumour Biol 37 (2016) 2901-2908. 
[28] J. Zhu, J. Zuo, Q. Xu, et al., Isocitrate 
dehydrogenase mutations may be a protective 
mechanism in glioma patients, Med Hypotheses 
76 (2011) 602-603. 
[29] M.D. Feldkamp, S.E. O'Donnell, L. Yu, et al., 
Allosteric effects of the antipsychotic drug 
trifluoperazine on the energetics of calcium 
binding by calmodulin, Proteins 78 (2010) 2265-
2282. 
[30] M.D. Feldkamp, L. Gakhar, N. Pandey, et al., 
Opposing orientations of the anti-psychotic 
drug trifluoperazine selected by alternate 
conformations of M144 in calmodulin, Proteins 
83 (2015) 989-996. 
[31] F.M. Bokhovchuk, N. Bate, N.V. 
Kovalevskaya, et al., The Structural Basis of 
Calcium-Dependent Inactivation of the 
12 
 
Transient Receptor Potential Vanilloid 5 Channel, 
Biochemistry 57 (2018) 2623-2635. 
[32] S. Kang, H. Kwon, H. Wen, et al., Global 
dynamic conformational changes in the 
suppressor domain of IP3 receptor by stepwise 
binding of the two lobes of calmodulin, FASEB 
J 25 (2011) 840-850. 
 
 
